NCT00331045View on ClinicalTrials.gov

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2006

Study Completion Date

December 31, 2006

Conditions
CancerConstipation
Interventions
DRUG

alvimopan

0.25 mg/day

DRUG

Placebo

DRUG

Alvimopan 0.5 mg/day

DRUG

Alvimopan 1 mg/day

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00331045 - Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid | Biotech Hunter | Biotech Hunter